Lipocine (LPCN)
(Delayed Data from NSDQ)
$5.27 USD
-0.17 (-3.13%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $5.45 +0.18 (3.42%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Income Statements
Fiscal Year end for Lipocine Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | -3 | 1 | 16 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | -3 | 1 | 16 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 15 | 13 | 13 | 18 | 13 |
Income After Depreciation & Amortization | -18 | -12 | 3 | -18 | -13 |
Non-Operating Income | 2 | 1 | -4 | -3 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -16 | -11 | -1 | -21 | -13 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -16 | -11 | -1 | -21 | -13 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -16 | -11 | -1 | -21 | -13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -19 | -12 | 4 | -18 | -13 |
Depreciation & Amortization (Cash Flow) | -1 | 0 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -18 | -12 | 3 | -18 | -13 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5.27 | 5.23 | 5.11 | 3.28 | 1.52 |
Diluted EPS Before Non-Recurring Items | -3.14 | -2.21 | 0.68 | -6.46 | -8.50 |
Diluted Net EPS (GAAP) | -3.14 | -2.21 | -0.17 | -6.46 | -8.50 |
Fiscal Year end for Lipocine Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.22 | -3.12 | 0.00 | 0.05 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.22 | -3.12 | 0.00 | 0.05 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.80 | 3.92 | 3.96 | 4.40 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.58 | -7.04 | -3.96 | -4.35 |
Non-Operating Income | NA | 0.31 | 0.39 | 0.41 | 0.47 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -2.28 | -6.65 | -3.55 | -3.87 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.28 | -6.65 | -3.55 | -3.87 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.28 | -6.65 | -3.55 | -3.87 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 5.27 | 5.29 | 5.24 | 5.20 |
Diluted EPS Before Non-Recurring Items | NA | -0.42 | -1.27 | -0.68 | -0.68 |
Diluted Net EPS (GAAP) | NA | -0.51 | -1.27 | -0.68 | -0.68 |